ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 02/05/2014

ClinicalTrials.gov ID: NCT00595270

Study Identification

Unique Protocol ID:	IC51-305
Brief Title:	Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Official Title:	Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Secondary IDs:	

Study Status

Record Verification:	February 2014
Overall Status:	Completed
Study Start:	October 2005
Primary Completion:	September 2007 [Actual]
Study Completion:	April 2009 [Actual]

Sponsor/Collaborators

Sponsor:	Valneva Austria GmbH
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? No Delayed Posting?

IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CBER IND/IDE Number: 8589 Serial Number: 0028 Has Expanded Access? No
Review Board:	Approval Status: Approved Board Name: Paul-Ehrlich-Institut Board Affiliation: Paul-Ehrlich-Institut Phone: Email:
Data Monitoring?:	No
Plan to Share Data?:	
Oversight Authorities:	Germany: Paul-Ehrlich-Institut United Kingdom: Medicines and Healthcare Products Regulatory Agency United States: Food and Drug Administration

Study Description

Brief Summary:	The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose
Detailed Description:	This is an open label, non-randomized multi-center phase 3 follow-up study. All volunteers having completed trial IC51-304 (NCT00595790) will be enrolled into this trial at 2 sites

Conditions

Conditions:	Japanese Encephalitis
Keywords:	

Study Design

Study Type:	Interventional
Primary Purpose:	Prevention
Study Phase:	Phase 3
Intervention Model:	Single Group Assignment
Number of Arms:	
Masking:	Open Label

Allocation:	N/A
Endpoint Classification:	Efficacy Study
Enrollment:	349 [Actual]

Arms and Interventions

Arms	Assigned Interventions
IC51 In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.	Biological/Vaccine: IC51 Other Names: • Japanese Encephalitis purified inactivated vaccine

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years
Maximum Age:	
Gender:	Both
Accepts Healthy Volunteers?:	Yes
Criteria:	Inclusion Criteria:

- At least 18 years of age
- Written informed consent obtained prior to study entry
- Subjects correctly included in and having completed study IC51-304 according to the protocol.

Exclusion Criteria:

- Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period
- Immunodeficiency including post-organ-transplantation or immunosuppressive therapy

• Pregnancy, lactation or unreliable contraception in female subjects

Contacts/Locations

Study Officials: Susanne Eder
Study Director
Intercell AG

Locations:

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Reporting Groups

	Description
IC51 2 x 6 µg	treatment group in preceeding study IC51-304
IC51 1 x 12 µg	treatment group in preceeding study IC51-304
IC51 1 x 6 µg	treatment group in preceeding study IC51-304

Overall Study

	IC51 2 x 6 µg	IC51 1 x 12 µg	IC51 1 x 6 µg
Started	116	117	116
Completed	110	107	108
Not Completed	6	10	8

Baseline Characteristics

Reporting Groups

	Description
IC51 2 x 6 µg	treatment group in preceeding study IC51-304
IC51 1 x 12 µg	treatment group in preceeding study IC51-304
IC51 1 x 6 µg	treatment group in preceeding study IC51-304

Baseline Measures

	IC51 2 x 6 µg	IC51 1 x 12 µg	IC51 1 x 6 µg	Total
Number of Participants	116	117	116	349
Age, Categorical [units: participants]				
<=18 years	0	0	0	0
Between 18 and 65 years	109	108	106	323
>=65 years	7	9	10	26
Gender, Male/Female [units: participants]				
Female	67	60	57	184
Male	49	57	59	165
Region of Enrollment Europe [units: participants]	116	117	116	349

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination

Measure Description	Seroprotection rate (SPR) (anti-JEV neutralizing antibody titer ≥ 1:10) 24 months (M24) after the primary vaccination - imputed; Persistence of immunogenicity (SPR) at M24 defined as:
	• pos. (positive) (persistent): Subjects
	  • with a non-missing, pos. seroconversion at D56 (Study IC51-304) and
	  • without booster at M11 or M23 and
	  • with non-missing, seroprotection (SP) pos. PRNT50 at M6 or M12 and
	  • with non-missing, SP pos. PRNT50 at M24
	• neg. (negative) (non-persistent): Subjects with
	  • missing or neg. seroconversion at D56 (Study IC51-304) or
	  • booster at M11 or at M23, or
	  • non-missing, SP neg. PRNT50 at M6 or M12 or
	  • missing PRNT50 at both M6 and M12 or
	  • missing or SP neg. PRNT50 (serum dilution giving 50% reduction in plaques in a Plaque Reduction Neutralization Test) at M24

Time Frame	- 24 months
Safety Issue?	No

Analysis Population Description

ITT (Intent-To-Treat) Population: included all subjects rolled over from study IC51-304; analyzed according to treatment to which they were randomized in IC51-304

Reporting Groups

	Description
IC51 2 x 6 µg	treatment group in preceeding study IC51-304
IC51 1 x 12 µg	treatment group in preceeding study IC51-304
IC51 1 x 6 µg	treatment group in preceeding study IC51-304

Measured Values

	IC51 2 x 6 µg	IC51 1 x 12 µg	IC51 1 x 6 µg
Number of Participants Analyzed	116	117	116
Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination [units: percentage of participants] Number (95% Confidence Interval)	56 (39.4 to 57.3)	7 (3.0 to 11.9)	5 (1.8 to 9.6)

2. Secondary Outcome Measure:

Measure Title	SPR 24 Months After the Primary Vaccination (Observed)
Measure Description	Persistence of immunogenicity (SPR) at M24 (observed) defined as : • positive (persistent): Subjects • with a non-missing, positive seroconversion at D56 (Study IC51-304), and • who did not receive a booster dose at Visit 2 (M11) or Visit 4 (M23), and • with a non-missing, SP positive PRNT50 result at Visit 1 (M6) or Visit 3 (M12), and • with a non-missing, SP positive PRNT50 result at Visit 5 (M24) • negative (non-persistent): Subjects • with missing or negative seroconversion at D56 (Study IC51-304), or • who did receive a booster dose at Visit 2 (M11) or at Visit 4 (M23), or • with a non-missing, SP negative PRNT50 result at Visit 1 (M6) or Visit 3 (M12), or • with a missing PRNT50 result at both Visit 1 (M6) and Visit 3 (M12), or • with a non-missing, SP negative PRNT50 result at Visit 5 (M24)
Time Frame	24 months
Safety Issue?	No

Outcome Measure Data Not Reported

3. Secondary Outcome Measure:

Measure Title	Persistent and Actual SPR 6, 12 and 24 Months After Primary Vaccination
Measure Description	
Time Frame	- 24 months
Safety Issue?	No

Outcome Measure Data Not Reported

4. Secondary Outcome Measure:

Measure Title	Persistent and Actual GMT 6, 12 and 24 Months After Primary Vaccination
Measure Description	
Time Frame	24 months
Safety Issue?	No

Outcome Measure Data Not Reported

5. Secondary Outcome Measure:

Measure Title	SCR 1 Month After the Booster Doses
Measure Description	
Time Frame	1 month
Safety Issue?	No

Outcome Measure Data Not Reported

6. Secondary Outcome Measure:

Measure Title	GMT 1month After Booster Doses
Measure Description	
Time Frame	1 month
Safety Issue?	No

Outcome Measure Data Not Reported

7. Secondary Outcome Measure:

Measure Title	Safety Profile of IC51
Measure Description	
Time Frame	study duration
Safety Issue?	Yes

Outcome Measure Data Not Reported

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	[Not specified]

Reporting Groups

	Description
IC51 2 x 6 µg	treatment group in preceeding study IC51-304
IC51 1 x 12 µg	treatment group in preceeding study IC51-304
IC51 1 x 6 µg	treatment group in preceeding study IC51-304

Serious Adverse Events

	IC51 2 x 6 µg	IC51 1 x 12 µg	IC51 1 x 6 µg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	4/116 (3.45%)	4/117 (3.42%)	3/116 (2.59%)
Infections and infestations			
Appendicitis	1/116 (0.86%)	0/117 (0%)	0/116 (0%)
Injury, poisoning and procedural complications			
Facial Bones Fracture	0/116 (0%)	1/117 (0.85%)	0/116 (0%)
Hand Fracture	0/116 (0%)	0/117 (0%)	1/116 (0.86%)
Tendon Injury	0/116 (0%)	1/117 (0.85%)	0/116 (0%)
Musculoskeletal and connective tissue disorders			
Back Pain	0/116 (0%)	1/117 (0.85%)	0/116 (0%)
Intervertebral Disc Protrusion	1/116 (0.86%)	0/117 (0%)	0/116 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon Cancer	0/116 (0%)	0/117 (0%)	1/116 (0.86%)
Renal and urinary disorders			
Urinary Incontinence	1/116 (0.86%)	0/117 (0%)	0/116 (0%)
Reproductive system and breast disorders			
Uterine Prolapse	0/116 (0%)	0/117 (0%)	1/116 (0.86%)
Respiratory, thoracic and mediastinal disorders			
Paranasal Sinus Discomfort	1/116 (0.86%)	0/117 (0%)	0/116 (0%)
Surgical and medical procedures			
Hysterectomy	0/116 (0%)	1/117 (0.85%)	0/116 (0%)

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 1%

	IC51 2 x 6 µg	IC51 1 x 12 µg	IC51 1 x 6 µg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	61/116 (52.59%)	69/117 (58.97%)	64/116 (55.17%)
Blood and lymphatic system disorders			
Anaemia	0/116 (0%)	0/117 (0%)	2/116 (1.72%)
Lymphadenopathy	2/116 (1.72%)	1/117 (0.85%)	0/116 (0%)
Gastrointestinal disorders			
Abdominal Pain Upper	1/116 (0.86%)	2/117 (1.71%)	0/116 (0%)
Diarrhoea	3/116 (2.59%)	3/117 (2.56%)	0/116 (0%)
Nausea	1/116 (0.86%)	6/117 (5.13%)	4/116 (3.45%)
Toothache	2/116 (1.72%)	1/117 (0.85%)	2/116 (1.72%)
Vomiting	2/116 (1.72%)	1/117 (0.85%)	1/116 (0.86%)
General disorders			
Fatique	5/116 (4.31%)	7/117 (5.98%)	6/116 (5.17%)
Induration	1/116 (0.86%)	0/117 (0%)	2/116 (1.72%)
Influenza Like Ilness	7/116 (6.03%)	5/117 (4.27%)	6/116 (5.17%)
Injection Site Pain	0/116 (0%)	2/117 (1.71%)	1/116 (0.86%)
Infections and infestations			
Herpes Zoster	1/116 (0.86%)	0/117 (0%)	2/116 (1.72%)
Lower Respiratory Tract Infection	2/116 (1.72%)	0/117 (0%)	1/116 (0.86%)
Nasopharyngitis	12/116 (10.34%)	13/117 (11.11%)	11/116 (9.48%)
Pharyngitis	0/116 (0%)	0/117 (0%)	2/116 (1.72%)
Sinusitis	3/116 (2.59%)	0/117 (0%)	1/116 (0.86%)
Injury, poisoning and procedural complications			
Accidental Poisoning	1/116 (0.86%)	3/117 (2.56%)	0/116 (0%)
Procedural Pain	1/116 (0.86%)	2/117 (1.71%)	0/116 (0%)
Investigations			

	IC51 2 x 6 µg	IC51 1 x 12 µg	IC51 1 x 6 µg
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Haematocrit Decreased	0/116 (0%)	2/117 (1.71%)	0/116 (0%)
Haemoglobin Decreased	0/116 (0%)	2/117 (1.71%)	0/116 (0%)
Red Blood Cell Count Decreased	0/116 (0%)	2/117 (1.71%)	0/116 (0%)
Musculoskeletal and connective tissue disorders			
Back Pain	3/116 (2.59%)	4/117 (3.42%)	2/116 (1.72%)
Myalgia	1/116 (0.86%)	4/117 (3.42%)	5/116 (4.31%)
Pain In Extremity	2/116 (1.72%)	0/117 (0%)	1/116 (0.86%)
Nervous system disorders			
Headache	10/116 (8.62%)	12/117 (10.26%)	13/116 (11.21%)
Hypoaesthesia	2/116 (1.72%)	0/117 (0%)	0/116 (0%)
Reproductive system and breast disorders			
Dysmenorrhoea	3/116 (2.59%)	1/117 (0.85%)	1/116 (0.86%)
Respiratory, thoracic and mediastinal disorders			
Cough	5/116 (4.31%)	2/117 (1.71%)	2/116 (1.72%)
Nasal Congestion	0/116 (0%)	2/117 (1.71%)	0/116 (0%)
Pharyngolaryngeal Pain	5/116 (4.31%)	5/117 (4.27%)	3/116 (2.59%)
Rhinorrhoea	1/116 (0.86%)	2/117 (1.71%)	2/116 (1.72%)
Sinus Congestion	0/116 (0%)	2/117 (1.71%)	0/116 (0%)
Skin and subcutaneous tissue disorders			
Eczema	0/116 (0%)	0/117 (0%)	2/116 (1.72%)
Rash	2/116 (1.72%)	2/117 (1.71%)	4/116 (3.45%)

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Official Title: Senior Manager Clinical Research
Organization: Intercell AG
Phone: +43 1 206 20 Ext: 0
Email: kdubischar.kastner@intercell.com